Enhertu beats standard care in lung cancer trial on key metric

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. SAP
7. CSX
8. LRCX
9. KNX
10. ELV

Go back to Enhertu beats standard care in lung cancer trial on key metric

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTI

September 13, 2026 9:55 PM EDT

6-month improvement in median progression-free survival vs. pembrolizumab plus chemotherapy

AstraZeneca and Daiichi Sankyos ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care in a Phase III trial in this setting

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyos ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as a 1st-line treatment of patients with... More